Skip to main content

Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure.

Publication ,  Journal Article
Figueroa, JF; Wadhera, RK; Frakt, AB; Fonarow, GC; Heidenreich, PA; Xu, H; Lytle, B; DeVore, AD; Matsouaka, R; Yancy, CW; Bhatt, DL; Joynt Maddox, KE
Published in: JAMA Cardiol
December 1, 2020

IMPORTANCE: Medicare Advantage (MA), a private insurance plan option, now covers one-third of all Medicare beneficiaries. Although patients with cardiovascular disease enrolled in MA have been reported to receive higher quality of care in the ambulatory setting than patients enrolled in fee-for-service (FFS) Medicare, it is unclear whether MA is associated with higher quality in patients hospitalized with heart failure, or alternatively, if incentives to reduce utilization under MA plans may be associated with worse care. OBJECTIVE: To determine whether there are differences in quality of care received and in-hospital outcomes among patients enrolled in MA vs FFS Medicare. DESIGN, SETTING, AND PARTICIPANTS: Observational, retrospective cohort study of patients hospitalized with heart failure in hospitals participating in the Get With the Guidelines-Heart Failure registry. EXPOSURES: Medicare Advantage enrollment. MAIN OUTCOMES AND MEASURES: In-hospital mortality, discharge disposition, length of stay, and 4 heart failure achievement measures. RESULTS: Of 262 626 patients hospitalized with heart failure, 93 549 (35.6%) were enrolled in MA and 169 077 (64.4%) in FFS Medicare. The median (interquartile range) age was 78 (70-85) years for patients enrolled in MA and 78 (69-86) years for patients enrolled in FFS Medicare. Standard mean differences in age, sex, prevalence of comorbidities, or objective measures on admission, including vital signs and laboratory values, were less than 10%. After adjustment, there were no statistically significant differences in receipt of evidence-based β-blockers when indicated; angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitors at discharge; measurement of left ventricular function; and postdischarge appointments by Medicare insurance type. Patients enrolled in MA, however, had higher odds of being discharged directly home (adjusted odds ratio [AOR], 1.16; 95% CI, 1.13-1.19; P < .001) relative to patients enrolled in FFS Medicare and lower odds of being discharged within 4 days (AOR, 0.97; 95% CI, 0.93-1.00; P = .04). There was no significant difference in in-hospital mortality between patients with MA and patients with FFS Medicare (AOR, 0.98; 95% CI, 0.92-1.03; P = .42). CONCLUSIONS AND RELEVANCE: Among patients hospitalized with heart failure, no observable benefit was noted in quality of care or in-hospital mortality between those enrolled in MA vs FFS Medicare, except lower use of post-acute care facilities. As MA continues to grow, it will be important to ensure that participating private plans provide an added value to the patients they cover to justify the higher administrative costs compared with traditional FFS Medicare.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

December 1, 2020

Volume

5

Issue

12

Start / End Page

1349 / 1357

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Retrospective Studies
  • Quality of Health Care
  • Medicare Part C
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Figueroa, J. F., Wadhera, R. K., Frakt, A. B., Fonarow, G. C., Heidenreich, P. A., Xu, H., … Joynt Maddox, K. E. (2020). Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiol, 5(12), 1349–1357. https://doi.org/10.1001/jamacardio.2020.3638
Figueroa, Jose F., Rishi K. Wadhera, Austin B. Frakt, Gregg C. Fonarow, Paul A. Heidenreich, Haolin Xu, Barbara Lytle, et al. “Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure.JAMA Cardiol 5, no. 12 (December 1, 2020): 1349–57. https://doi.org/10.1001/jamacardio.2020.3638.
Figueroa JF, Wadhera RK, Frakt AB, Fonarow GC, Heidenreich PA, Xu H, et al. Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiol. 2020 Dec 1;5(12):1349–57.
Figueroa, Jose F., et al. “Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure.JAMA Cardiol, vol. 5, no. 12, Dec. 2020, pp. 1349–57. Pubmed, doi:10.1001/jamacardio.2020.3638.
Figueroa JF, Wadhera RK, Frakt AB, Fonarow GC, Heidenreich PA, Xu H, Lytle B, DeVore AD, Matsouaka R, Yancy CW, Bhatt DL, Joynt Maddox KE. Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiol. 2020 Dec 1;5(12):1349–1357.

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

December 1, 2020

Volume

5

Issue

12

Start / End Page

1349 / 1357

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Retrospective Studies
  • Quality of Health Care
  • Medicare Part C
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Female